{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-008888","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.445327+00:00","generated_at":"2026-06-06T10:58:33.135714+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silo Pharma prioritizes 2024 pipeline targeting PTSD, chronic pain, neurology; plans Pre-IND for SPC-15 by Q2","bullets":["Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.","SP-26 is a non-opioid, time-release ketamine implant for fibromyalgia, potential first at-home ketamine treatment.","SPC-14 (Alzheimer's) positive animal results; more data expected in 2024; SPU-16 targets MS via homing peptide.","FDA 505(b)(2) pathway to be used for SPC-15, SP-26, and SPC-14 to expedite approval and reduce costs.","Pipeline includes four drugs across three therapeutic areas: mental health, chronic pain, and neurology."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-008888","json":"https://secwatch.observer/filing/0001213900-24-008888.json","markdown":"https://secwatch.observer/filing/0001213900-24-008888.md","text":"https://secwatch.observer/filing/0001213900-24-008888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/0001213900-24-008888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/ea192611-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:58:33.135714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}